Prognostic implications of DNA aneuploidy in 156 untreated multiple myeloma patients

Authors

  • R. GARCIA-SANZ,

    1. The Castelano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies Department of Haematobgy, University Hospital of Salamanca, University of Salamanca, Salamanca, Spain
    Search for more papers by this author
  • A. ORFAO,

    1. The Castelano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies Department of Haematobgy, University Hospital of Salamanca, University of Salamanca, Salamanca, Spain
    Search for more papers by this author
  • M. GONZALEZ,

    1. The Castelano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies Department of Haematobgy, University Hospital of Salamanca, University of Salamanca, Salamanca, Spain
    Search for more papers by this author
  • MA J. MORO,

    1. The Castelano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies Department of Haematobgy, University Hospital of Salamanca, University of Salamanca, Salamanca, Spain
    Search for more papers by this author
  • J. M. HERNANDEZ,

    1. The Castelano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies Department of Haematobgy, University Hospital of Salamanca, University of Salamanca, Salamanca, Spain
    Search for more papers by this author
  • F. ORTEGA,

    1. The Castelano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies Department of Haematobgy, University Hospital of Salamanca, University of Salamanca, Salamanca, Spain
    Search for more papers by this author
  • D. BORREGO,

    1. The Castelano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies Department of Haematobgy, University Hospital of Salamanca, University of Salamanca, Salamanca, Spain
    Search for more papers by this author
  • M. CARNERO,

    1. The Castelano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies Department of Haematobgy, University Hospital of Salamanca, University of Salamanca, Salamanca, Spain
    Search for more papers by this author
  • F. CASANOVA,

    1. The Castelano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies Department of Haematobgy, University Hospital of Salamanca, University of Salamanca, Salamanca, Spain
    Search for more papers by this author
  • R. JIMENEZ,

    1. The Castelano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies Department of Haematobgy, University Hospital of Salamanca, University of Salamanca, Salamanca, Spain
    Search for more papers by this author
  • J. A. PORTERO,

    1. The Castelano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies Department of Haematobgy, University Hospital of Salamanca, University of Salamanca, Salamanca, Spain
    Search for more papers by this author
  • J. F. SAN MIGUEL

    Corresponding author
    1. The Castelano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies Department of Haematobgy, University Hospital of Salamanca, University of Salamanca, Salamanca, Spain
      Dr Jesus F. San Miguel, Servicio de Hematologia, Hospital Universitario de Salamanca, Paseo de San Vicente 58-182, 37007. Salamanca. Spain.
    Search for more papers by this author

Dr Jesus F. San Miguel, Servicio de Hematologia, Hospital Universitario de Salamanca, Paseo de San Vicente 58-182, 37007. Salamanca. Spain.

Abstract

In this study the incidence of DNA aneuploidy in a large series of untreated multiple myeloma (MM) patients was assessed in order to determine its clinical and prognostic significance. A total of 156 MM patients were included in the study. DNA measurements were performed in all cases at diagnosis using two different flow cytometry methods: (1) propidium iodide (PI) staining on isolated nuclei, and (2) CD38/PI double staining on whole cells. The DNA ploidy status was correlated with the most relevant clinical and haematological disease characteristics. From the 156 cases analysed, 91 (58%) were aneuploid (56% hyperdiploid and 2% hypodiploid). The correlation between the two techniques on the detection of DNA aneuploidy was excellent, although CD38/PI double staining would be preferable in cases with <5% of DNA aneuploid plasma cells (PC). Upon comparing the clinical and haematological disease characteristics of hyperdiploid versus diploid cases, the former group was characterized by a lower age, reduced incidence of anaemia, lower 02M levels, higher proliferative activity within the residual normal haemopoietic cells, increased expression of CD 5 6 antigen in PC, and higher proportion of PB CD4+ T cells. In contrast, diploid cases had a higher expression of the CD10, CD20 and CD15 antigens and greater numbers of PB CD56+CD3 NK cells (P < 0–05). Circulating PC were identified in six cases, all being diploid. Overall survival was significantly longer in hyperdiploid compared to diploid MM (P = 0–02).

Ancillary